Long-term Efficacy of Interferon in Severe Uveitis Associated with Behcet Disease

被引:40
|
作者
Diwo, Eleonore [1 ]
Gueudry, Julie [2 ]
Saadoun, David [3 ]
Weschler, Bertrand [3 ]
LeHoang, Phuc [1 ]
Bodaghi, Bahram [1 ]
机构
[1] Hop La Pitie Salpetriere, Dept Ophthalmol, 47-83 Blvd Hop, F-75013 Paris, France
[2] Charles Nicolle Hosp, Dept Ophthalmol, Rouen, France
[3] Hop La Pitie Salpetriere, Dept Internal Med, Paris, France
关键词
Behcet disease; interferon therapy; panuveitis; REFRACTORY POSTERIOR UVEITIS; ALPHA THERAPY; INFLIXIMAB; SAFETY; RECOMMENDATIONS; INVOLVEMENT; PANUVEITIS; MANAGEMENT;
D O I
10.1080/09273948.2016.1206204
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To retrospectively assess the frequency of ocular relapse and the possibility of long-term remission in patients treated with interferon (IFN) for severe uveitis associated with Behcet disease. Methods: All patients were treated with an initial dosage of 3 million IU IFN three times a week. The main outcome measure was the number of relapses per person per year before, during, and after IFN treatment. Results: Of 36 patients (67 eyes), 31 (86.1%) responded to IFN. The mean follow-up was 8.19 years. Twenty-one out of 36 patients discontinued IFN and 76% of these have not relapsed within 5.05 years after discontinuation. The mean relapse per person per year decreased significantly from 1.39 to 0.0496 (p = 1.82x10(-10)) during the treatment period and remained at 0.057 relapses per person per year after IFN discontinuation. Conclusion: IFN efficiently decreases the relapse rate and seems to permit long-term remission even after discontinuation.
引用
收藏
页码:76 / 84
页数:9
相关论文
共 50 条
  • [41] INTERFERON ALPHA FOR TREATMENT OF UVEITIS IN BEHCET'S DISEASE
    Dubey, Rahul
    Wakefield, Dennis
    McCluskey, Peter
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2011, 39 : 39 - 39
  • [42] MONTHLY INTRAVITREAL INFLIXIMAB IN BEHcET'S DISEASE ACTIVE POSTERIOR UVEITIS A Long-Term Safety Study
    Refaat, Mohammad
    Abdullatif, Abdussalam M.
    Hamza, Mostafa M.
    Macky, Tamer A.
    El-Agha, Mohamed-Sameh H.
    Ragab, Gaafar
    Soliman, Mahmoud M.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2021, 41 (08): : 1739 - 1747
  • [43] Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis
    Miserocchi, Elisabetta
    Modorati, Giulio
    Berchicci, Luigi
    Pontikaki, Irene
    Meroni, Pierluigi
    Gerloni, Valeria
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2016, 100 (06) : 782 - 786
  • [44] Long-term efficacy of infliximab on background vascular leakage in patients with Behcet's disease
    Keino, H.
    Okada, A. A.
    Watanabe, T.
    Taki, W.
    EYE, 2014, 28 (09) : 1100 - 1106
  • [45] Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behcet disease uveitis and concomitant bladder papillary carcinoma
    Orlando, Ida
    Vitale, Antonio
    Rigante, Donato
    Lopalco, Giuseppe
    Fabiani, Claudia
    Cantarini, Luca
    INTERNAL MEDICINE JOURNAL, 2017, 47 (09) : 1086 - 1088
  • [46] Long-term prognosis of Behcet's disease.
    Chen, LL
    Funamoto, Y
    Yamamoto, K
    Tanaka, M
    Shimakawa, M
    Hori, S
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2001, 42 (04) : S463 - S463
  • [47] Uveitis associated with cancer immunotherapy: long-term outcomes
    Fardeau, Christine
    Bencheqroun, Mehdi
    Levy, Arielle
    Bonnin, Sophie
    Ferchaud, Marie-Adelaide
    Fardeau, Leila
    Coscas, Florence
    Bodaghi, Bahram
    Lebrun-Vignes, Benedicte
    IMMUNOTHERAPY, 2021, 13 (18) : 1465 - 1481
  • [48] SHORT AND LONG-TERM FOLLOW-UP WITH ADALIMUMAD IN REFRACTORY UVEITIS ASSOCIATED TO BEHCET'S DISEASE. MULTICENTER STUDY OF 74 PATIENTS
    Dominguez-Casas, L.
    Calvo-Rio, V.
    Beltran, E.
    S-Burson, J.
    Mesquida, M.
    Adan, A.
    Hernandez, M.
    H-Grafella, M.
    V-Pascual, E.
    M-Costa, L.
    Sellas, A.
    Cordero-Coma, M.
    Diaz-Llopis, M.
    Gallego, R.
    Salom, D.
    G-Serrano, J.
    Ortego, N.
    Herreras, J.
    G-Aparicio, A.
    Maiz, O.
    Blanco, A.
    Torre, I.
    Diaz-Valle, D.
    Pato, E.
    Aurrecoechea, E.
    Caracuel, M.
    Gamero, F.
    Minguez, E.
    Carrasco, C.
    Olive, A.
    Vazquez, J.
    R-Moreno, O.
    Manero, J.
    Munoz, S.
    Gandia, M.
    Rubio-Romero, E.
    Toyos-SMiera, F.
    Lopez-Longo, F.
    Nolla, J.
    Revenga, M.
    Vegas-Revenga, N.
    Fernandez-Diaz, C.
    Demetrio-Pablo, R.
    Gonzalez-Gay, M.
    Blanco, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 326 - 326
  • [49] LONG-TERM TNFα ANTAGONISTS TREATMENT EFFICACY IN AUTOIMMUNE UVEITIS
    De La Iglesia Salgado, J.
    Ruiz Tudela, M.
    Garcia Muro, A.
    Menor Almagro, R.
    Ruiz Benitez, M.
    Rodriguez Suarez, A.
    Perez Venegas, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1107 - 1107
  • [50] Use of recombinant interferon alpha 2 for the treatment of autoimmune uveitis (primary or associated with Behcet disease)
    Roman, JS
    Aguilera, MCP
    Palma, MJC
    Medina, CO
    Pena, AT
    LopezCheca, F
    Wichmann, I
    REVISTA CLINICA ESPANOLA, 1996, 196 (05): : 293 - 298